Company news
Tenaya Therapeutics, Inc. news in 2022
Tenaya Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
December 6, 2022
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
November 27, 2022
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
Tenaya Therapeutics Announces Closing of Public Offering
November 20, 2022
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022
November 3, 2022
Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress
October 3, 2022
Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences
September 28, 2022
Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions
September 28, 2022
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
September 5, 2022
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
September 5, 2022
Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 9, 2022
Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
July 5, 2022
Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics
June 15, 2022
Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference
May 19, 2022
Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022
Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 2, 2022
Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022
April 27, 2022
Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates
March 22, 2022
Tenaya Therapeutics Provides 2022 Business Updates
January 9, 2022
Decks in 2022
- Technical Presentation (2022)
Technical · 15 slides · 2022